Loading...
Please wait, while we are loading the content...
Similar Documents
Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers
| Content Provider | MDPI |
|---|---|
| Author | Jantarabenjakul, Watsamon Sodsai, Pimpayao Chantasrisawad, Napaporn Jitsatja, Anusara Ninwattana, Sasiprapa Thippamom, Nattakarn Ruenjaiman, Vichaya Tan, Chee Wah Pradit, Rakchanok Sophonphan, Jiratchaya Wacharapluesadee, Supaporn Wang, Lin-Fa Puthanakit, Thanyawee Hirankarn, Nattiya Putcharoen, Opass |
| Copyright Year | 2022 |
| Description | Inactivated SARS-CoV-2 vaccine (CoronaVac) is commonly used in national immunization programs. However, the immune response significantly declines within a few months. Our study assessed the immune response against SARS-CoV-2 after receiving booster shots of BNT162b2 or ChAdOx1 among health care workers who previously received CoronaVac as their primary immunization. Fifty-six participants who received ChAdOx1 and forty-two participants who received BNT162b2 were enrolled into this study, which evaluated immune responses, including anti-SARS-CoV-2 spike total antibodies $(Elecsys^{®}$), surrogated viral neutralization test (sVNT) to ancestral strain (cPass™; GenScript), five variants of concern (Alpha, Beta, Gamma, Delta, and Omicron) (Luminex; multiplex sVNT) and the ELISpot with spike (S1 and S2) peptide pool against the ancestral SARS-CoV-2 strain. The samples were analyzed at baseline, 4, and 12 weeks after primary immunization, as well as 4 and 12 weeks after receiving the booster. This study showed a significant increase in anti-SARS-CoV-2 spike total antibodies, sVNT, and T-cell immune response after the booster, including against the Omicron variant. Immune responses rapidly decreased in the booster group at 12 weeks after booster but were still higher than post-primary vaccination. A fourth dose or a second booster should be recommended, particularly in health care workers. |
| Starting Page | 639 |
| e-ISSN | 2076393X |
| DOI | 10.3390/vaccines10050639 |
| Journal | Vaccines |
| Issue Number | 5 |
| Volume Number | 10 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-04-19 |
| Access Restriction | Open |
| Subject Keyword | Vaccines Infectious Diseases Covid-19 Sars-cov-2 Anti-sars-cov-2 Spike Total Antibodies Surrogate Viral Neutralizing Antibody T-cell Immune Response Coronavac Chadox1 Bnt162b2 Booster |
| Content Type | Text |
| Resource Type | Article |
